The CEO of NervGen explicitly states his goal is to commercialize their spinal cord injury drug independently, not to position the company for an acquisition. This long-term, mission-driven focus on getting a drug to market shapes strategic decisions and contrasts with a common build-to-sell mentality in biotech.

In today's tightened market, a brilliant scientific platform isn't enough to secure investment. Investors have shifted to a product-focused lens, requiring founders to present a clear, detailed pathway from their idea to an approved drug. This includes defining the unmet medical need and outlining the proposed clinical trial design from day one.

The founder of Project Insulin reveals it took five and a half years of work—primarily fundraising and planning—just to sign the contract with a CDMO to begin drug development. This highlights the immense, often invisible, runway required before the 'real' scientific work starts, demanding extreme patience and long-term commitment.

CEO Michael Metzger views the high-risk, capital-intensive clinical development phase as a "project" focused on investment and milestones. The organization only transitions into a "business" at the key turning point of drug approval and commercial launch. This mental model helps manage resources and expectations through the long, uncertain pre-commercial journey.

The greatest barrier to biomedical advancement is the exorbitant cost ($25M+) and time (18+ months) required for the FDA's initial new drug (IND) application. By adopting a faster, notification-based system like Australia's, the U.S. could unlock a wave of innovation, lower costs, and prevent the industry from offshoring to China.

Investors evaluate risk differently based on a company's stage. For early-stage ventures, the primary question is clinical risk: 'will the drug work?'. CMC and manufacturing are secondary. However, for late-stage (Phase 3) companies, manufacturing readiness becomes a critical diligence area where a two-year delay could be fatal.

Drug development can take a decade, a timeframe that misaligns with typical investor horizons and employee careers. Success requires navigating fluctuating capital market cycles and implementing strategies to retain key scientific talent for the long haul.

For a successful drug launch, biotech companies must abandon a sequential, siloed approach. The key is to start early, using an agile model where all functions (medical, commercial, regulatory) work in an integrated way from the outset. Rushing this complex process leads to costly mistakes.

While passion for helping patients is a powerful motivator, founders must learn to frame their pitch around value creation for investors. This means explicitly connecting the science and clinical benefit to the commercial market, reimbursement strategy, and ultimate financial return for their limited partners.